Gilead hires Eli Lilly's bio-medicines head Christi Shaw to lead Kite unit

Gilead Sciences said Thursday that it appointed Christi Shaw to be chief executive officer of its Kite subsidiary and become a member of Gilead's senior leadership team. Earlier in the day, Eli Lilly had announced that Shaw would be stepping down from her current role as president of Lilly Bio-Medicines at the end of August, to be replaced by Patrik Jonsson.

"We conducted an extensive search for a new leader at Kite and we believe that [Shaw's] unique set of skills will allow us to continue to build on our leadership position in cell therapy," commented Gilead CEO Daniel O'Day. He added that Shaw's "vast experience across complex therapeutic areas, and particularly in oncology, will serve Kite very well."

Shaw stated that she "[looks] forward to working with the many talented individuals in this organisation, as we change the way cancer is treated and bring forward important, life-saving therapies." Prior to joining Eli Lilly, Shaw had served as president of Novartis and North American head of Novartis Oncology. 

Gilead completed its $11.9-billion takeover of Kite in 2017.

Meanwhile, other recent leadership changes at Gilead include hiring former Bristol-Myers Squibb executive Johanna Mercier as its chief commercial officer. Earlier this year, Alessandro Riva stepped down from his post as executive vice president of Gilead's oncology therapeutics unit to serve as CEO of Glenmark Pharmaceuticals' US-based innovation company, while chief financial officer Robin Washington is retiring from Gilead in March 2020.  

To read more Top Story articles, click here.